MX366154B - Composiciones de vacuna del virus del dengue y metodos de uso de las mismas. - Google Patents
Composiciones de vacuna del virus del dengue y metodos de uso de las mismas.Info
- Publication number
- MX366154B MX366154B MX2015017384A MX2015017384A MX366154B MX 366154 B MX366154 B MX 366154B MX 2015017384 A MX2015017384 A MX 2015017384A MX 2015017384 A MX2015017384 A MX 2015017384A MX 366154 B MX366154 B MX 366154B
- Authority
- MX
- Mexico
- Prior art keywords
- dengue
- vaccine
- dengue virus
- methods
- vaccine compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a composiciones de vacuna del virus del dengue que comprenden una primera y una segunda vacuna de dengue, en donde la primera vacuna de dengue es una vacuna viva atenuada de dengue y la segunda vacuna de dengue es una vacuna de subunidad de dengue recombinante o una vacuna de dengue desactivada; en donde la vacuna viva atenuada de dengue comprende por lo menos un virus vivo atenuado de dengue o por lo menos un flavivirus quimérico vivo atenuado; las composiciones de vacuna del virus del dengue de la invención pueden comprender adicionalmente uno o más adyuvantes; en modalidades preferidas de la invención, la primera y segunda vacuna de dengue son tetravalentes; la invención también se refiere a métodos de uso de las composiciones de vacuna del virus del dengue de la invención para tratar o prevenir la infección por dengue, o para prevenir, mitigar o retrasar el inicio o avance de las manifestaciones clínicas de la misma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361837721P | 2013-06-21 | 2013-06-21 | |
PCT/US2014/042625 WO2014204892A1 (en) | 2013-06-21 | 2014-06-17 | Dengue virus vaccine compositions and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015017384A MX2015017384A (es) | 2016-04-06 |
MX366154B true MX366154B (es) | 2019-06-28 |
Family
ID=52105172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015017384A MX366154B (es) | 2013-06-21 | 2014-06-17 | Composiciones de vacuna del virus del dengue y metodos de uso de las mismas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9861692B2 (es) |
EP (1) | EP3010536A4 (es) |
JP (1) | JP2016523251A (es) |
KR (1) | KR20160023683A (es) |
CN (1) | CN105246506A (es) |
AU (1) | AU2014281713A1 (es) |
BR (1) | BR112015031226A2 (es) |
MX (1) | MX366154B (es) |
MY (1) | MY187896A (es) |
PH (1) | PH12015502666B1 (es) |
SG (1) | SG11201510266SA (es) |
WO (1) | WO2014204892A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016106107A2 (en) | 2014-12-22 | 2016-06-30 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
WO2017023839A1 (en) | 2015-08-03 | 2017-02-09 | The United States Of America As Represented By The Secretary Of The Navy | Immune enhancing recombinant dengue protein |
WO2017056101A1 (en) * | 2015-09-30 | 2017-04-06 | Panacea Biotec Limited | Stable live attenuated recombinant dengue vaccine |
WO2018217906A1 (en) * | 2017-05-23 | 2018-11-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus serotype 4 epitopes |
BR112020011205A8 (pt) | 2017-12-07 | 2023-02-07 | Merck Sharp & Dohme | Formulações de composições de vacina contra o vírus da dengue |
CN111346079B (zh) * | 2020-02-24 | 2023-06-20 | 南方医科大学 | 细菌dna促旋酶抑制剂brd7716作为治疗和/或预防登革病毒感染的药物及其制药用途 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6190859B1 (en) | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
EP0836090A1 (en) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Method of analysis of samples by determination of the distribution of specific brightnesses of particles |
ATE468858T1 (de) | 1997-02-28 | 2010-06-15 | Acambis Inc | Chimäre impfstoffe gegen flaviviren |
EP1005363B1 (en) | 1997-07-31 | 2006-03-29 | Hawaii Biotech, Inc. | Recombinant dimeric envelope vaccine against flaviviral infection |
AU774045B2 (en) | 1998-09-02 | 2004-06-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Dengue viruses that are replication defective in mosquitos for use as vaccines |
WO2000057908A2 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research, Department Of The Army | Attenuated dengue-1 virus vaccine |
CA2365411A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
ES2322327T3 (es) | 1999-03-26 | 2009-06-19 | Walter Reed Army Institute Of Research | Vacuna multivalente contra el virus del dengue. |
WO2000057910A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-4 virus vaccine |
US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
CA2755964C (en) | 2001-05-22 | 2017-06-27 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
NZ534159A (en) | 2002-01-15 | 2007-03-30 | Acambis Inc | Vaccines comprising flaviviruses with one or more hinge region mutations that reduce viscerotropism of the flaviviruses |
EP2338508B1 (en) * | 2002-05-03 | 2018-02-14 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A rDEN3/4delta 30(ME), rDEN2/4delta30(ME) or rDEN1/4delta30(ME) recombinant chimeric dengue virus containing a 30 nucleotide deletion (delta30) in a section of the 3' untranslated region of dengue type 4 genome, wherein said 30 nucleotide deletion corresponds to the TL2 stem-loop structure |
AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
US7189403B2 (en) | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
CA2584228C (en) | 2004-10-20 | 2015-05-05 | Acambis Inc. | Vaccines against japanese encephalitis virus and west nile virus |
MX2007015873A (es) | 2005-06-17 | 2008-04-22 | Sanofi Pasteur | Cepa atenuada de virus de dengue serotipo 1. |
WO2006134443A1 (en) | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
MX2007016083A (es) | 2005-06-24 | 2008-03-10 | Intervet Int Bv | Vacunas quimericas inactivadas y metodos relacionados de uso. |
CA2616026A1 (en) | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
AR061197A1 (es) | 2006-06-07 | 2008-08-13 | Sanofi Pasteur | Cepas del virus 3 del dengue vivas atenuadas |
DK2589602T3 (en) | 2006-08-15 | 2016-07-25 | The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of | Development of dengue virus vaccine components |
FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
WO2008127307A2 (en) | 2006-11-09 | 2008-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
US9198964B2 (en) | 2010-10-29 | 2015-12-01 | Merck Sharp & Dohme Corp. | Recombinant subunit dengue virus vaccine |
AU2013295016A1 (en) | 2012-07-24 | 2015-01-29 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
-
2014
- 2014-06-17 AU AU2014281713A patent/AU2014281713A1/en not_active Abandoned
- 2014-06-17 CN CN201480031059.5A patent/CN105246506A/zh active Pending
- 2014-06-17 US US14/898,515 patent/US9861692B2/en active Active
- 2014-06-17 BR BR112015031226A patent/BR112015031226A2/pt not_active Application Discontinuation
- 2014-06-17 SG SG11201510266SA patent/SG11201510266SA/en unknown
- 2014-06-17 KR KR1020157035588A patent/KR20160023683A/ko not_active Application Discontinuation
- 2014-06-17 JP JP2016521494A patent/JP2016523251A/ja active Pending
- 2014-06-17 EP EP14814205.2A patent/EP3010536A4/en not_active Withdrawn
- 2014-06-17 MY MYPI2015002912A patent/MY187896A/en unknown
- 2014-06-17 MX MX2015017384A patent/MX366154B/es active IP Right Grant
- 2014-06-17 WO PCT/US2014/042625 patent/WO2014204892A1/en active Application Filing
-
2015
- 2015-11-27 PH PH12015502666A patent/PH12015502666B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2016523251A (ja) | 2016-08-08 |
KR20160023683A (ko) | 2016-03-03 |
PH12015502666A1 (en) | 2016-03-07 |
MX2015017384A (es) | 2016-04-06 |
US9861692B2 (en) | 2018-01-09 |
SG11201510266SA (en) | 2016-01-28 |
US20160151477A1 (en) | 2016-06-02 |
EP3010536A4 (en) | 2016-11-30 |
WO2014204892A1 (en) | 2014-12-24 |
CN105246506A (zh) | 2016-01-13 |
EP3010536A1 (en) | 2016-04-27 |
PH12015502666B1 (en) | 2016-03-07 |
AU2014281713A1 (en) | 2015-11-12 |
MY187896A (en) | 2021-10-27 |
BR112015031226A2 (pt) | 2017-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502666A1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
MX2018007627A (es) | Vacuna contra el virus del zika. | |
MX2017001406A (es) | Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva. | |
EA201290956A1 (ru) | Вакцина против вич | |
PH12017500450A1 (en) | Flavivirus virus like particle | |
WO2013106689A8 (en) | Hcv ns3 protease inhibitors | |
EA201790517A1 (ru) | Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции | |
PH12017501165A1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
EA201290792A1 (ru) | Пептиды для вакцины против аллергии на березу | |
PH12015501721A1 (en) | Porcine parvovirus 5b, methods of use and vaccine | |
MX2013003245A (es) | Vacuna contra virus de diarrea viral de bovinos. | |
PH12016500960A1 (en) | Hendra and nipah virus g glycoprotein immunogenic compositions | |
WO2014140166A3 (en) | Vaccine | |
EA201590678A1 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
WO2015086738A3 (en) | Hiv vaccine | |
JOP20190214A1 (ar) | ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها | |
EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
MX2021006543A (es) | Vacuna. | |
MX2014001158A (es) | Virus recombinantes de influenza porcina y usos del mismo. | |
EA202090236A1 (ru) | Иммуногенные композиции senecavirus a и способы с ними | |
EA201390452A1 (ru) | Вакцина | |
EA201892348A1 (ru) | Комбинации и способы, включающие ингибитор сборки капсида |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |